Accounts Payable (Quarterly) Chart

View Accounts Payable (Quarterly) for BCLI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Accounts Payable (Quarterly) Chart
Start Trial

Historical Accounts Payable (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 7.488M
March 31, 2026 7.317M
December 31, 2025 7.067M
September 30, 2025 6.42M
June 30, 2025 5.997M
March 31, 2025 6.797M
December 31, 2024 6.08M
September 30, 2024 4.603M
June 30, 2024 5.34M
March 31, 2024 4.69M
December 31, 2023 4.954M
September 30, 2023 3.926M
June 30, 2023 5.19M
March 31, 2023 7.802M
December 31, 2022 6.224M
September 30, 2022 6.395M
June 30, 2022 5.292M
March 31, 2022 4.57M
December 31, 2021 3.70M
September 30, 2021 2.739M
June 30, 2021 3.00M
March 31, 2021 2.552M
December 31, 2020 5.417M
September 30, 2020 3.283M
June 30, 2020 4.604M
Date Value
March 31, 2020 4.571M
December 31, 2019 14.68M
September 30, 2019 9.144M
June 30, 2019 8.765M
March 31, 2019 5.029M
December 31, 2018 4.548M
September 30, 2018 2.602M
June 30, 2018 4.182M
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.275M
June 30, 2017 0.227M
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 1.304M
June 30, 2014 0.00
March 31, 2014 0.326M

Accounts Payable Definition

Represents amounts due to suppliers of goods and/or services used in the company's operations, generally not interest-bearing, and as yet unpaid at the prior fiscal period-end and expected to be paid within the current period. Data for this field is generally not available prior to 1989.

Read full definition.

Accounts Payable (Quarterly) Range, Past 5 Years

View Accounts Payable (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Accounts Payable (Quarterly) Benchmarks

View Accounts Payable (Quarterly) Benchmarks
Start Trial
NovelStem International Corp. 0.00
Summit Therapeutics, Inc. 22.90M
Kezar Life Sciences, Inc. 0.273M
Protara Therapeutics, Inc. 4.663M
Clene, Inc. 1.142M